Cosenza M - Search Results

1

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

Cosenza M, Civallero M, Sacchi S, Marcheselli R, Pozzi S. Cosenza M, et al. Leuk Lymphoma. 2005 Feb;46(2):257-63. doi: 10.1080/10428190400014991. Leuk Lymphoma. 2005. PMID: 15621810

2

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S. Neri A, et al. Among authors: cosenza m. Leuk Lymphoma. 2008 Jul;49(7):1374-83. doi: 10.1080/10428190802078289. Leuk Lymphoma. 2008. PMID: 18452078

3

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.

Civallero M, Cosenza M, Grisendi G, Marcheselli L, Todoerti K, Sacchi S. Civallero M, et al. Among authors: cosenza m. Leuk Lymphoma. 2010 Apr;51(4):671-9. doi: 10.3109/10428191003637290. Leuk Lymphoma. 2010. PMID: 20218811

4

Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.

Cosenza M, Civallero M, Grisendi G, Marcheselli L, Roat E, Bari A, Sacchi S. Cosenza M, et al. Ann Hematol. 2012 Oct;91(10):1613-22. doi: 10.1007/s00277-012-1490-6. Epub 2012 May 24. Ann Hematol. 2012. PMID: 22623160

5

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

Civallero M, Cosenza M, Marcheselli L, Pozzi S, Sacchi S. Civallero M, et al. Among authors: cosenza m. Expert Opin Investig Drugs. 2012 Nov;21(11):1597-606. doi: 10.1517/13543784.2012.719871. Epub 2012 Aug 25. Expert Opin Investig Drugs. 2012. PMID: 22920938

6

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

Cosenza M, Civallero M, Pozzi S, Marcheselli L, Bari A, Sacchi S. Cosenza M, et al. Hematol Oncol. 2015 Dec;33(4):166-75. doi: 10.1002/hon.2179. Epub 2014 Nov 13. Hematol Oncol. 2015. PMID: 25394177

7

Activity of BKM120 and BEZ235 against Lymphoma Cells.

Civallero M, Cosenza M, Pozzi S, Bari A, Ferri P, Sacchi S. Civallero M, et al. Among authors: cosenza m. Biomed Res Int. 2015;2015:870918. doi: 10.1155/2015/870918. Epub 2015 Oct 18. Biomed Res Int. 2015. PMID: 26557706 Free PMC article.

8

Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.

Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S. Cosenza M, et al. Apoptosis. 2017 Jun;22(6):827-840. doi: 10.1007/s10495-017-1364-4. Apoptosis. 2017. PMID: 28315173 Free PMC article.

9

Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.

Civallero M, Cosenza M, Pozzi S, Sacchi S. Civallero M, et al. Among authors: cosenza m. Oncotarget. 2017 Oct 23;8(61):103797-103814. doi: 10.18632/oncotarget.21951. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262601 Free PMC article.

10

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.

Verdelli D, Nobili L, Todoerti K, Intini D, Cosenza M, Civallero M, Bertacchini J, Deliliers GL, Sacchi S, Lombardi L, Neri A. Verdelli D, et al. Among authors: cosenza m. Hematol Oncol. 2009 Mar;27(1):23-30. doi: 10.1002/hon.875. Hematol Oncol. 2009. PMID: 18759374

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters